Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

The key events that shaped the Medtech Insight Top 100 by sales in 2019

04 Dec 2020

2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

The latest Medtech Insight sales ranking of the top 100 publicly-traded medtech manufacturers is COVID-19-affected for a relatively sizeable proportion of companies ̶ those whose reporting periods closed during 2020. The effect of the pandemic on their sales was often significant, and gave a foretaste of what the rest of the industry will experience when filing calendar year 2020 accounts.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Birmingham City University Develops New Defense Mechanism Against Cyberattacks On AI Systems

11 Apr 2025

• By Natasha Barrow

AI systems used in healthcare are vulnerable to adversarial cyberattacks, which are a growing concern, said Atif Azad, a professor of AI at Birmingham City University. Azad’s research group has developed a method that trains AI to become more resilient to cyber threats through the use of random image adjustments.

Opportunity For Medtech To Contribute To EU Cybersecurity Recommendations

11 Apr 2025

• By Amanda Maxwell

The deadline for comments is 30 June 2025

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

10 Apr 2025

• By Marion Webb

Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.